Merck Extends Global Enterprise License of Metacore and Metabase
News Jan 12, 2006
Merck researchers around the world will continue to use the MetaCore data mining suite in research and development activities.
The researchers will also retain direct access to MetaBase, a comprehensive database of mammalian protein interactions, signaling and metabolic pathways, bioactive compounds, and diseases manually curated by GeneGo from full text experimental literature.
MetaCore and MetaBase have been integrated with Merck’s discovery informatics platform and are leveraged across multiple therapeutic areas.
"Merck has been a great partner, and we have enjoyed interacting with their scientists," said Julie Bryant, VP business development.
"As a result of this collaboration, we have developed a number of new data analysis and visualization features now available in MetaCore."
"We will continue to encourage this high level of communication as we move forward in 2006."
"The field of functional data analysis is maturing rapidly, and it is crucial for us to work closely with state-of-art research teams, such as those at Merck."
In new studies a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia. Unlike its experimental predecessors, the new drug does not appear to cause systemic side effects or overcorrect with excessive blood oxygenation, which can itself be toxic. Instead, the new drug delivers its precious oxygen cargo only to the tissues that need it most.READ MORE
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
The sweet flavors’ appeal to teens is a major concern for Food and Drug Administration officials, who recently declared teen vaping an epidemic. New research shows flavorings are transforming more than marketing. The chemical additives react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.READ MORE